TESTDNA To Launch ColoAlert Test In Poland For Mainz Biomed

A new test called ColoAlert can catch colorectal cancer early. This can help save lives. The test works by finding certain molecules in the blood. When these molecules are present, it could mean that a person has colorectal cancer. Early detection is very important for treating cancer. This test can make it easier for doctors to catch the cancer early.

Mainz Biomed and TESTDNA have teamed up to sell ColoAlert tests in Poland. The ColoAlert test is used for molecular genetics diagnostics. The partnership is a commercial agreement.

At-home detection test for colorectal cancer now available. It's called ColoAlert. Mainz Biomed offers the test. Both companies will work together to market the test in Poland. They plan to do this in the coming weeks. The aim is to fully launch the test in the Polish market.

Darin Leigh, the CCO of Mainz Biomed, said that they were excited to partner with TESTDNA to bring ColoAlert to the Polish market. This partnership is a big step for Mainz Biomed.

We have a new partner called TESTDNA. They're joining our network of labs who want to use modern tools to help patients stay healthy. TESTDNA focuses on deadly diseases like CRC, which is one of the leading causes of cancer deaths in Europe. We're excited to have them on board!

The ColoAlert test can detect colorectal cancer. It's less invasive than other tests. It's better at detecting cancer early. It's better than fecal occult blood tests.

This test uses PCR technology. It finds more cases of colorectal cancer than other stool tests.

The test is sold in some EU countries. It's sold through company health programs, direct sales, and independent labs.

The ReconAAsense study in the US will evaluate the test.